AVXL

Anavex Life Sciences Corp. (AVXL)

About Anavex Life Sciences Corp. (AVXL)

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Details

Daily high

$8.78

Daily low

$8.26

Price at open

$8.41

52 Week High

$10.45

52 Week Low

$3.25

Market cap

731.8M

Dividend yield

0.00%

Volume

2.5M

Avg. volume

1.5M

P/E ratio

-17.22

Anavex Life Sciences Corp. News